|
|
|
|
||
Re: OK you trading gurus...in the end... with knowledge of having two efficacious vaccines, which are without peer, and which would have worldwide demand and use, a buyout price would have to be … have to reflect the huge, annual market... well $20 per share to $40 a share. anything less would be silly... Going it alone, with a marketing and production partner, would bring eventual share price higher thank $40 over a few years... RSV will be efficacious for all ages which will be born out after more trials. Nanoflu combined with RSV will be a mind blower... shareholders simply must wait patiently. |
return to message board, top of board |